These studies demonstrated improvement in biochemical profiles , with a decline in or normalization of liver enzymes .
However , some concerns have been raised regarding the use of vitamin E in patients with NASH due to its adverse effects profile and lack of significant improvement in hepatic fibrosis .
There has been a growing interest in the role of vitamin E supplementation in the treatment and /or prevention of nonalcoholic fatty liver ( NAFLD ) .
Furthermore , histological assessment showed favorable outcomes in lobular inflammation and hepatic steatosis following treatment with vitamin E. Current guidelines regarding the use of vitamin E in the setting of NAFLD recommend that vitamin E-based treatment be restricted to biopsy-proven nondiabetic patients with NASH only .
Vitamin D supplementation for the treatment of non-alcoholic fatty liver disease: A randomized double blind placebo controlled trial.
BACKGROUND Low serum vitamin D has been associated with metabolic syndrome and Non-alcoholic fatty liver disease ( NAFLD ) . This study aim ed to investigate the impact of vitamin D supplementation in treatment of patients with NAFLD . METHODS In a double blind , r and omized ,  placebo  controlled trial patients with NAFLD were r and omized to receive one weekly pearl of placebo , 50,000 U vitamin D3 ( cholecalciferol ) pearl per week and 0.25 mg calcitriol ( 1,25 dihydroxycholecalciferol ) pearl per day for 3 months . RESULTS 106 NAFLD patients were r and omized to receive calcitriol , vitamin D3 and placebo pearls for 12 weeks and data for 91 patients were analyzed . After 12 weeks of treatment , serum alkaline phosphatase levels was significantly decreased from baseline levels in vitamin D and calcitriol treated groups ( P < 0.05 ) . Serum and gamma glutamyl transferase ( GGT ) level was also significantly decreased compared to the baseline levels after 12 weeks of treatment with vitamin D. There was no statistically significant difference between placebo , calcitriol , vitamin D groups in terms of serum aminotransferase , alkaline phosphatase , serum GGT and lipid profile ( P > 0.05 ) . CONCLUSION While significant reduction of serum alkaline phosphatase and GGT were seen with vitamin D and calcitriol supplementation from baseline levels , no beneficial effects was seen when comparing vitamin D , calcitriol and placebo groups at the end of trial
These studies demonstrated improvement in biochemical profiles , with a decline in or normalization of liver enzymes .
However , some concerns have been raised regarding the use of vitamin E in patients with NASH due to its adverse effects profile and lack of significant improvement in hepatic fibrosis .
There has been a growing interest in the role of vitamin E supplementation in the treatment and /or prevention of nonalcoholic fatty liver ( NAFLD ) .
Furthermore , histological assessment showed favorable outcomes in lobular inflammation and hepatic steatosis following treatment with vitamin E. Current guidelines regarding the use of vitamin E in the setting of NAFLD recommend that vitamin E-based treatment be restricted to biopsy-proven nondiabetic patients with NASH only .